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Abstract
Mucus hydration is important in mucus clearance and lung health. This study sought to test the 
relative utility of spontaneous sputum (SS) vs. the reasonably non-invasive induced sputum (IS) 
samples for measurement of mucus hydration. SS and IS samples were collected over a two-day 
study interval. Sputum was induced with escalating inhaled nebulized 3–5% hypertonic saline. 
Viscous portions of the samples (“plugs”) were utilized for percent solids and total mucin 
analyses. Cytokines, nucleotides/nucleosides, and cell differentials were measured in plugs diluted 
into 0.1% Sputolysin. Overall, 61.5% of chronic bronchitis (CB) subjects produced a SS sample 
and 95.2% an IS sample. Total expectorate sample weights were less for the SS (0.94 ± 0.98 g) 
than the IS (2.67 ± 2.33 g) samples. Percent solids for the SS samples (3.56% ± 1.95; n=162) were 
significantly greater than the IS samples (3.08% ± 1.81; n=121), p=0.133. Total mucin 
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concentrations also exhibited a dilution of the IS samples: SS=4.15 ±3.23 mg/ml (n=62) vs IS= 
3.34 ± 2.55 mg/ml (n=71) (p=0.371). Total mucins (combined SS and IS) but not percent solids, 
were inversely associated with FEV1 percent predicted (p=0.052) and FEV1/FVC % (p=0.035). 
There were no significant differences between sample types in cytokine or differential cell counts. 
The probability of sample collections was less for SS than IS samples. Measurements of hydration 
revealed modest dilution of the IS samples compared to SS. Thus for measurements of mucus 
hydration, both SS and IS samples appear to be largely interchangeable.
Keywords
Spontaneous sputum; induced sputum; percent solids; total mucin; nucleotides; cytokines; 
neutrophils
Introduction
We have recently demonstrated that mucus hydration may prove to be a useful biomarker for 
diagnosing chronic bronchitis (CB) and identifying COPD (Chronic Obstructive Pulmonary 
Disease) sub-types.1–3 Sputum has been a useful biomarker for assessment of the 
inflammation and microbiologic status of COPD subjects, suggesting it may be useful for 
measurement of mucus hydration. Not all COPD patients, however, consistently produce a 
spontaneous sputum (SS) sample. Accordingly, hypertonic saline (HS) inhalation has been 
used to induce sputum production in subjects with muco-obstructive lung diseases, including 
asthma 4,5 and COPD.6,7
There are similarities and differences in SS vs. IS samples. Both SS and IS are likely derived 
from large airways that develop high flow velocities during cough, producing a sample from 
a common site.8,9 SS samples are less perturbed by intervention than IS samples, but as 
noted above, SS often cannot be consistently obtained at a visit in CB patients. Conversely, 
time and personnel availability limit access to IS samples. Previous comparisons of 
biomarkers in SS vs. IS in COPD subjects have suggested that the two sputum sample types 
produce similar information but these analyses have generally focused on evaluations of 
inflammatory markers, e.g., cytokines and differential cell counts.10–12
This study was designed to assess sample types suitable for measures of mucus 
concentration (hydration) and mediators that regulate mucus hydration (nucleotides) in 
subjects with CB. Such a comparison is particularly relevant to IS measures of mucus 
hydration because of the possibility that HS inhalation will hydrate (dilute) endogenous 
mucus. Accordingly, we compared the SS vs. IS sampling techniques utilizing measures of 
sputum hydration, including percent solids, mucin concentration, and nucleotide and 
nucleoside levels as our primary aim, in a cohort of well-defined CB subjects.
Methods
This study captured stable baseline periods from a CB cohort (n=69) who fit criteria for 
GOLD Stage 0-III with three sub-studies: 1) a cross-sectional, single baseline sub-study of 
CB subjects (n=47); 2) a longitudinal exacerbation sub-study with two sequential baseline 
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periods (n=30); and 3) a baseline period from an interventional sub-study (n=15) 
(Clinicaltrials.gov NCT00903955). Each baseline period encompassed visits on two 
successive days (Supplementary Figure 1A). Twenty-three subjects participated in more than 
one sub-study.
CB was defined as chronic mucus production and cough for at least 3 months per year for 2 
successive years. Inclusion and exclusion criteria were previously described.1 Patients had 
not received oral steroids or antibiotics for >4 weeks prior to baseline visits and sample 
collection. All subjects withheld bronchodilators (short- or long-acting) for the morning of 
the visits. The study was approved by the University of North Carolina Institutional Review 
Board, and all subjects provided written informed consent.
Sputum collection and processing
On day one of each baseline period, SS samples as available, a physical exam, vital signs, 
oxygen saturation and spirometry pre- and post-albuterol were obtained. On day two of each 
baseline period, a SS sample was collected if available and clinical assessments repeated. 
Sputum was then induced with escalating concentrations of nebulized 3–5% hypertonic 
saline (DeVilbiss UltraNeb 2000 Ultrasonic nebulizer).8 Induction was terminated if >200 
mg of selected plug material was obtained, or if >200 mg was not obtained after the 5% HS 
challenge. For each baseline period, it was possible to obtain three sputum samples: two SS 
samples (day 1 and day 2) and one IS sample on day 2.
Sputum samples were delivered to the UNC Sputum Core Lab within 15 minutes of 
collection. The mucus gel “plug” selection approach was utilized 4 and samples prioritized 
for analysis, as determined by sample weight (Supplementary Figure 1B). Purulent sputum 
(strong yellow - green in color), was not processed due to suspicion of active infection. For 
the determination of percent solids, “plug” samples were selected, weighed, and then dried 
overnight at 65oC. Wet to dry ratios were calculated and reported as percent solids.13 The 
sample was then examined, the remaining mucus gel “plugs” selected, weighed, and placed 
in a pre-weighed container.8 A portion (100–500 mg) of the mucus gel plugs were diluted 
with guanidine reduction buffer (0.5%) for mucin analysis by size exclusion 
chromatography combined with differential refractometry.14 The remaining mucus gel plugs 
were diluted into a solution of dithiothreitol (0.1%) in EDTA (1mM) for analyses of: 1) 
sputum adenosine (ADO) and adenine nucleotides (ATP, ADP and AMP), ethenoderivatized 
and quantified by HPLC analysis15; and 2) total cell counts and differentials (Hema-Stain-3; 
Fisher Scientific, Hampton, NH). Cytokines were measured as previously described.16 
Cytokine measures are only reported for values that are within the limits of detection. 
Sputum quality was assessed by percent squamous epithelial cells (SEC) as a marker of 
salivary contamination and visual inspection. 17
Statistical analysis
Statistical analyses were conducted using SAS and SAS JMP Pro 12 (Cary, NC). All results 
are reported as means ± SD, and n as indicated. Values were log transformed to correct for 
normality when necessary. Correlations were determined by Spearman’s or Pearson’s 
correlations as appropriate. A logistic regression model was fit to determine the odds of 
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producing spontaneous sputum, adjusting for disease severity as determined by FEV1 
percent predicted and FEV1 / FVC percent, current smoking status, age, sex, pack-years, 
race and the use of inhaled steroids (ICS). Effects of HS concentration, visit number and SS-
IS differences for percent solids and total mucin were analyzed with a mixed-model 
regression using sample type as fixed and subject number as random effects. Age, race, sex, 
current smoking status, pack-years, FEV1 percent predicted, month of visit and inhaled 
corticosteroid use were evaluated as covariates. All subjects had complete data for each 
covariate. Only significant covariates are reported. Paired analyses on the same day of the 
first baseline visit utilized a paired t test. All tests were 2-sided with a 0.05 significance 
level. Data are presented as outlier box plots which show all data points with the box 
representing the 25% and 75% quartile, the horizontal red line as the median, and the 
“whiskers” drawn to the furthest point within 1.5 times the interquartile range.
Results
Demographics
Subject demographics are listed in Table 1. The subjects, age 31–80, were primarily white 
males, with a post-bronchodilator FEV1 percent predicted of 63.4 ± 20.5% and an FEV1 / 
FVC % of 56.7 ± 15.5%. Subjects were classified by Gold Stage severity, as GOLD 0 
(n=15), GOLD 1 (n=3), GOLD 2 (n=28) and GOLD 3 (n=22), there were no GOLD 4 
subjects.18 Current smokers were equally distributed between men and women, were 9 years 
younger (54 vs. 63 years, p=0.0003), and had a higher FEV1 percent predicted than former 
smokers (67.8 vs. 59.8, p=0.130). Subject deposition for each of the three substudies utilized 
in the analyses is presented in Supplementary Figure 1A.
Subject sputum production and quality
Sixty-nine subjects participated in the study. Twenty-three subjects participated in more than 
one sub-study. The total sputum samples and percent possible sputum samples obtained at 
each sub-study baseline visit are presented in Supplementary Table 1. The likelihood of 
obtaining an SS sample at a study visit was 61.5% whereas the likelihood of obtaining an IS 
sample was 95.2%. Sex (p=0.110) or current smoking status (p=0.115) were not significant 
factors associated with the ability to produce an SS sample. Increasing age (p=0.022) was 
associated with increased likelihood of producing an SS sample. FEV1 percent predicted 
(p=0.026) and FEV1/FVC % (p=0.036) were inversely associated with SS sample 
production. Similarly, we found an increased likelihood of producing an SS sample as 
subjects progressed from GOLD stage 1 to GOLD stage 4 (67% to 86%). Sixty-four percent 
of SS producers were male and fifty percent of non-producers. In four of one hundred and 
twenty-six IS visits (3.2%), the IS procedure was stopped for anxiety (n=1) or declining 
FEV1 (n=3).
The mean ± SD of the % SECs for the SS and IS samples for which differential cell counts 
were determined, is 20.4 ± 28.3 % (n=46) and 17.9 ±22.9 % (n=81) respectively. Sixty-
seven percent of the SS samples and sixty-five percent of the IS samples had less than 20% 
SECs. We did observe a significant inverse correlation between percent SECs and percent 
solids (r = −0.43, p=0.002) for the SS samples and for the IS samples (r = −0.38, p=0.006). 
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There were no significant correlations of total mucin and percent SECs for either the SS or 
IS samples.
SS vs. IS samples weights
A total of 162 SS and 121 IS samples were obtained across all baseline visits. The total 
expectorated sample weight for the SS samples was 0.94 ± 0.98 g and 2.67 ± 2.33 g for the 
IS samples (Supplementary Figure 1C). Using a mixed model analysis, there were no 
differences in IS sample weights across the three HS concentrations; 3%=2.35 ± 1.19 g, 
4%=2.59 ± 2.13 g and 5%=3.16 ± 3.41 g (p=0.209). Sample weights decreased with ICS use 
(p=0.036) and increased as post-bronchodilator FEV1 percent predicted declined (p=0.025) 
in the model. Age, race, sex, current smoking status, pack-years, or month of visit were not 
significantly associated with sample weights.
Percent solids
Percent solids for each of the HS induction strengths are presented in Figure 1. No 
significant differences in percent solids as a function of HS induction concentration were 
observed (p=0.740). Therefore, percent solids measurements across all HS concentrations 
were used for the designated comparisons. No between-visit differences in sputum percent 
solids for the SS samples (p=0.352) or the IS samples (p=0.127) were detected 
(Supplementary Figure 2A and 2B). The percent solids measurements for all SS (n=162) and 
IS (n=121) samples is illustrated in Figure 2A. Mean values for the SS samples was 3.56 
± 1.95%, and the IS samples 3.08 ± 1.81%. Using a mixed model regression model (see 
methods), no significant difference between the SS and IS percent solids was found 
(p=0.133)., The covariates age, race, sex, current smoking status, pack-years, FEV1 percent 
predicted, month of visit and inhaled corticosteroid use were not significant in the model. 
Individual p values for each covariate for percent solids and total mucin are listed in 
Supplementay Table 2.
We also compared the SS and IS percent solids for forty-six paired samples collected on the 
same day. Only one pair of SS-IS samples were used per subject. SS samples were obtained 
prior to the IS induction (Figure 2B). There was no significant difference (p=0.937) between 
the SS samples (3.46 ± 2.05) and the IS samples (3.23 ± 1.76).
Total mucin
A significant overall difference (p=0.009) in total mucin as a function of HS induction 
concentration was observed (Figure 3). Mean ±SD values for the 3%, 4% and 5% HS 
concentrations is 3.49 ± 2.11, 4.21 ± 3.06 and 1.85 ± 1.10 respectively (p=0.003). No 
covariates were significant in the model. Total mucin concentrations for the SS and IS 
samples per baseline visit are presented in Supplementary Figure 3A and 3B. There were no 
significant differences between visits for either the SS (p=0.417) or the IS samples 
(p=0.749).
The total mucin measurements for the SS (n=62) and IS (n=71) samples is illustrated in 
Figure 4A. A similar trend in mucin dilution of the IS samples as with percent solids was 
observed. Mean values for the SS samples was 4.15 ± 3.23 mg/ml, and the IS samples 3.34 
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± 2.55 mg/ml. Using the mixed model analysis described in methods, no significant 
difference between the SS and IS percent solids was found (p=0.371). The covariates age, 
race, sex, current smoking status, pack-years, FEV1 percent predicted, month of visit and 
inhaled corticosteroid use were not significant.
Only eighteen paired SS and IS mucin samples were collected. (Figure 4B). Only one paired 
SS-IS mucin sample was used per subject. There was no significant difference (p=0.898) 
between the SS samples (4.13 ± 3.02) and the IS samples (4.01 ± 2.76).
Mucus hydration and pulmonary function
The association between percent solids and FEV1 percent predicted was evaluated by mixed 
model analysis. Age, sex and race were not included in the model since FEV1 percent 
predicted includes these corrections. The association between FEV1 and percent solids was 
not significant (p=0.114). Sample type (p=0.015) and ICS use (p=0.002) were significant in 
the model. Running the model separately for SS and IS or ICS use did not improve the 
association. Correlations of FVC percent predicted, FEV1 / FVC percent and FEF25–75 
percent predicted with percent solids were also evaluated (p=0.052, p=0.196 and p=0.688 
respectively). Sample type and ICS use were significant in each of the analyses.
Using the same mixed model to evaluate the association between total mucin and pulmonary 
function (FVC percent predicted, FEV1 percent predicted, FEV1 / FVC percent and 
FEF25–75 percent predicted). There was a trend of an inverse association between total 
mucin and FEV1 percent predicted (p=0.052) and with FEF25–75 percent predicted 
(p=0.068). FEV1 / FVC was inversely associated with total mucin (p=0.035) (Figure 5A and 
5B). There were no significant covariates including ICS use and sample type. Removing the 
covariates from the model improved the association of total mucin with FEV1 (p=0.015), 
FEV1 / FVC percent (p=0.022) and FEF25–75 (p=0.023).
Nucleotides/nucleosides, cell counts and cytokines
Baseline ATP and metabolites are presented by sample type in Table 2. Total adenine 
nucleotides/nucleosides (ATP+ADP+AMP+ADO) trended higher in the SS samples, 3814.7 
± 3263.0 nM (n=51) than the IS samples, 2904.3 ± 3050.6 nM (n=76), but the difference 
was not significant (p=0.085). There were no significant differences observed between the 
SS and IS samples for ATP or its metabolites.
The mean ± SD baseline differential cell counts are presented in Table 3. In general, counts 
as indexed by cells/mg trended lower in the IS samples, but no significant differences were 
detected. The percentage of each cell type was similar across SS vs. IS samples. The effect 
of increasing HS induction concentrations on differential cell counts in the IS samples was 
also analyzed. Twenty-eight subjects produced sufficient sample at 3% HS, 39 at 4% HS and 
19 subjects required 5% HS induction. Total cell counts (cells/mg of sputum) were not 
significantly different between HS induction concentrations; 2838 ± 6118 (n=29) cells/mg at 
3% HS; 4006 ± 1011 (n=40) cells/mg at 4%; and 2410 ± 1466 (n=19) cells/mg at 5% 
(p=0.607). The percent of bronchial epithelial cells progressively decreased with increasing 
HS concentrations from 2.8 ± (n=26) at 3% HS to 0.8 ± 1.0 (n=18)% at 5% HS. The percent 
of squamous epithelial cells, a possible marker of salivary contamination, was 25.3% ± 26.3 
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(n=27), 13.4% ± 21.9 (n=36) and 16.0% ± 17.2 (n=18) for 3, 4, and 5% HS, respectively 
(p=0.115).
A panel of cytokines was measured in a small number of SS and IS samples (Table 4). There 
were not enough samples to analyze differences in pairs from the same subject. Overall 
cytokine concentrations were not significantly different between the SS and IS samples. 
MIP-1α exhibited the strongest trend for SS values being higher than IS (p=0.052). Large 
SD values are noted for some cytokines, e.g. IL-3.
Discussion
The hydration state of mucus is a key variable that determines the efficiency of mucus 
clearance in health vs. disease, and is a major research focus of our group across several 
muco-obstructive diseases. Previous studies have related mucus hydration as measured by 
transbronchoscopic sampling to mucociliary clearance and FEV1 in CB subjects, suggesting 
mucus hydration may be a CB biomarker.1 Both spontaneous and induced sputum offer the 
opportunity to non- invasively measure mucus hydration in clinical and clinical research 
settings. The primary purpose of this study was to compare SS and IS for the assessment of 
mucus hydration. Both methods of sample acquisition have limitations in that SS is often not 
available especially in studies of early or mild disease and IS may not be appropriate for 
subjects with poor pulmonary function or during exacerbations.
The data describing the probability of obtaining a spontaneous sputum vs. induced sputum 
sample in this study mirrors previous reports.19,20 Namely, even though all study subjects 
met the classical definition of chronic bronchitis, the probability of producing an SS sample 
was only 60.9% at a single visit and was not predictable based on current smoking status or 
sex. Although our CB subjects included some GOLD stage 0, the majority of our samples 
from CB subjects were classified as GOLD stage 2 and 3, most likely enhancing the ability 
to obtain an SS sample, but may limit the interpretation of results to early and later stage 
disease. The observed association of an increased likelihood of producing an SS sample with 
increasing age and decreasing pulmonary function probably reflects a progression to more 
severe disease resulting in more mucus production. Thus, for research or clinical 
assessments, sputum induction with hypertonic saline is reliable for obtaining samples 
across disease severity.21
There were significant differences in IS vs. SS sample size that may be pertinent to clinical/
research needs. Measuring percent solids as an index of hydration requires 0.2 to 0.5 g of 
sputum and similar sample weights are required for total mucin measurements. 
Measurements of cell counts and soluble inflammatory mediators require an additional 0.2–
0.5 grams of sample. The sample weight of an SS sample, which was virtually all usable 
“plug” material, was 0.9 grams, at the margin of providing sufficient material for all 
analyses. Plug selection minimizes the selection/inclusion of saliva, which reduces 
squamous cell contamination and reduces the effect of dilution, which improves the quality 
of the sample. Approximately 50% of an IS sample is plug material.22 Thus, with ~ 50% of 
the ~ 2.7 gram IS sample weight useable by the plug selection technique, IS samples 
routinely provided sufficient material for all analyses.
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However, there were differences in the two sample types in measures of sputum hydration. 
Age, sex, race, current smoking status or ICS use were not significant factors in assessing SS 
vs IS measures of percent solids or total mucin. From analyses of sputum percent solids 
content of all obtained samples, HS induction yielded IS samples that were significantly less 
concentrated (~ 13%) compared to SS samples. Utilizing analyses of SS vs. IS sample pairs 
obtained at the same baseline visit, the SS sample percent solids were ~ 11% higher than the 
SS samples, but not statistically significant. A similar trend was observed for total mucin 
concentration, with the SS samples exhibiting on average ~ 11% higher total mucin 
concentrations than the IS samples. It was notable, however, that a larger dilution was 
observed for 5% HS induction (36%) vs. 3% (27%) or 4% (14%) HS induction. Collectively, 
there was evidence for a modest dilution of sputum following HS induction that may be 
dealt with in hydration analyses, if necessary, via correction factors.
HS induction likely produces the dilution of sputum via its osmotic actions to draw water 
onto airway surfaces.23 Indeed, recent reports have demonstrated HS induces expansion of 
the mucus layer as well as total airway surface liquid compartment, consistent with 
increased mucus hydration (dilution) of the mucus plugs selected as part of this protocol.24 
However, we cannot rule out that hydration was also perturbed by other mechanisms, e.g., 
HS-induced axonal reflexes and/or extracellular ATP release, that regulate mucus hydration.
25,26 Finally, it is also possible that HS-induced sputum dilution reflects a broad sampling of 
the lung that is not a feature of SS. Specifically, CB is a heterogeneous disease with areas of 
marked disease,27,28 likely producing hyperconcentrated, abnormal mucus, in parallel with 
areas of normal lung with normally hydrated mucus. It is, therefore, possible IS may sample 
mucus from both compartments, with the mucus “added” from normal areas to mucus from 
diseased areas, effectively diluting the composite sample.
We do not know whether the mucoid “plug” selection technique is optimal for sputum 
hydration analyses. In part, this uncertainty reflects the fact that it is not known whether 
mucus is inherently lumpy or smooth in vivo in health or disease.29,30 If mucus is inherently 
lumpy in vivo, plug selection may only sample one component of mucus. In this context, it 
was striking that the sputum weight of IS samples was much larger (~ 300% greater) than 
the SS samples, whereas the effects on plug dilution (percent solids and total mucin) was 
much smaller (~ 13% and 11%, respectively). It is unclear whether the larger IS total weight 
reflects: 1) HS-mediated rehydration of abnormal mucus and restoration of clearance or 2) 
addition of relatively well-hydrated mucus from normal areas to mucus from diseased areas 
(see above). With respect to the modest dilution of selected plugs, recent data suggest that 
mucus gels from subjects with muco-inflammatory diseases may be cross-linked, which 
limits solvent-induced swelling and produces gels (plugs) with constant (“permanent”) 
concentrations.31 The plug assessment technique, which selects “permanent” gels/plugs, 
may accurately detect the limited “swellability” of abnormal mucus but underestimate the 
effects of HS to dilute swellable (normal) mucus on the entire lung surface. Studies that 
directly compare the effects of dilution of the entire vs. plug-selected SS vs. SS samples will 
be required to comprehensively characterize the effects of HS induction on mucus/mucin 
concentration.
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HS-induced inflammation, via increased inflammatory cell numbers, theoretically could also 
perturb sputum percent solids measurements. For example, it has been reported that HS 
challenge results in increased sputum neutrophils at 8 and 24 hours post-HS challenge in 
healthy and asthmatic subjects.32,33 However, an increase in neutrophils was not observed 
during the HS challenge period.34 Regardless, to avoid inflammation-induced artifacts in our 
study, no IS samples were collected on successive days, and the SS samples were collected 
prior to IS samples. Notably, absolute neutrophil counts trended lower in the IS samples, 
whereas percent neutrophil values were unchanged. Collectively, these data suggest that 
neutrophilic inflammation was not acutely induced in our study, there was a modest dilution 
of neutrophil numbers by HS, and neutrophil numbers likely did not perturb percent solids 
measurements.
The concentration of adenine nucleotides/sides is tightly regulated in airway surface liquids 
to maintain normal mucus hydration.15 Nucleotide release from airway epithelia is very 
sensitive to mechanical or osmotic stresses and inflammation. Our data did not support an 
accelerated release of ATP from airway epithelia in response to HS induction, either directly 
from the epithelium or via an ingress of neutrophils. Indeed, total nucleotides and individual 
adenine nucleotide/nucleoside molecules, if anything, appeared modestly diluted by HS 
induction.
In contrast to our previous results 1 We found no relationship between percent solids of 
either the SS or IS sample types and pulmonary function. We attribute this to differences 
between bronchoscopic and spontaneous or induced sputum sampling, the former 
representative of a more distal airway sample which may correlate better with FEV1. 
Supporting this concept is the finding that approximately 33% of the SS and IS samples 
contained greater than 20% squamous epithelial cells suggesting significant salivary 
dilution. Squamous cells are one marker of potential sample dilution. Other methods of 
assessing dilution may need to be evaluated to assess the dilutional effect of sputum 
induction with HS.
Plug selection of IS samples may also reflect a composite of diseased and normal airway 
surfaces adding variability to the correlation with FEV1. In contrast, total mucin 
concentrations were inversely related to FEV1. A similar result was observed in a larger 
population utilizing induced sputum and GOLD stage in subjects with CB.3 The tighter 
association between mucins vs. percent solids and muco-obstruction in CB may reflect the 
fact that mucins dominate the mucus layer osmotic pressures and, hence, mucus clearance. 
Mucins comprise ~ 15% of percent solids, suggesting the percent solids measurement may 
contain more “noise”. The association between total mucin and FEV1 was stronger in the IS 
samples possibly because the IS samples and pulmonary function both represent diseased 
and non-diseased areas of the lung.3
Strengths of this study are that SS and IS are collected from the same subject, utilizing the 
same clinical research staff and a single processing center. Samples were delivered to the lab 
within 15 minutes of collection and processed immediately. This minimizes variability and 
strengthens the power to detect significant differences even with a relatively small number of 
subjects. Our sputum induction procedure and sample processing differs from other reported 
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methods so the results may not apply to other techniques. For example, we stopped 
induction at the lowest concentration of HS that produced a usable sample (generally at least 
1 g), as opposed to continuing induction through the 5 percent HS. Second we utilized the 
plug selection technique rather than the entire expectorated sample, which yields a smaller 
sample volume thus limiting the number of analyses that can be done. This is evident in the 
number of cytokine measures that was a lower priority for analysis when sputum volume 
was low. Because SS availability is not predictable and the study was not biased towards 
subjects that produced both sample types, paired comparisons become limiting, potentially 
decreasing the power to detect significant differences. A mixed model analysis optimized 
sample pairs adjusting for multiple samples obtained from the same subject.
Finally, both SS and IS sampling protocols should be suitable for repeat visit protocols. An 
analysis of percent solids for the SS and IS samples across serial baseline visits 
demonstrated no significance difference between visits. Collecting an SS sample at the 
beginning of the visit at which an IS sample was collected did not perturb the IS value as 
compared to IS samples collected without an antecedent SS sample (data not shown).
Conclusion
Utilizing the plug selection technique, both SS and IS samples are useful for assessing 
mucus hydration especially for mucin. Sputum induction with HS produces samples more 
reliably and in greater quantity that allows for more measurements to be completed. 
However, sample dilution in IS needs to be accounted for if SS and IS samples are 
interchangeably used in analyses. Additional studies are needed to assess the utility of non-
plug selected sputum processing.
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LIST OF ABBREVIATIONS
BD bronchodilator
BEC bronchial epithelial cell
CB chronic bronchitis
COPD chronic obstructive pulmonary disease
EDTA ethylenediaminetetraacetic acid
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FEV1 forced expiratory volume in one second









SEC squamous epithelial cell
SS spontaneous sputum
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Effect of hypertonic saline concentration on induced sputum percent solids. The mean ± SD 
percent solids for the HS concentrations of 3%, 4% and 5% are 3.13 ± 1.49 (n=35), 3.18 
± 2.12 (n=54), and 2.87 ± 1.59 (n=31) respectively. There was no significant difference 
between the HS concentrations (p=0.740).
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Comparison of SS and IS percent solids. (A) The SS mean ± SD is 3.56 ± 1.95% (n=162) 
and 3.08 ± 1.81% for the IS samples (n=121) (p=0.133). (B) Bland-Altman plot of paired 
samples collected on the same visit. The SS mean ± SD is 3.46 ± 2.05 and 3.23 ± 1.76 for 
the IS samples (p=0.937; n=46). The red solid line is the mean SS-IS difference, the red 
dotted line ± SE and the red dashed line ± SD.
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Effect of hypertonic saline concentration on induced sputum total mucin. The mean ± SD 
total mucin for the HS concentrations of 3%, 4% and 5% are 3.49 ± 2.11 (n=20), 4.21 ± 3.06 
(n=31), and 1.85 ± 1.10 (n=20) respectively. There was a significant difference between the 
HS concentrations (p=0.003).
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Comparison of SS and IS total mucin. A) SS mean ± SD is 4.15 ± 3.23 (n=62) and 3.34 
± 2.55 (n=71, p=0.371). B) Bland-Altman plot of paired samples collected on the same visit. 
The SS mean ± SD is 4.13 ± 3.02 and 4.01 ± 2.76 for the IS samples (p=0.898; n=18). The 
red solid line is the mean SS-IS difference, the red dotted line ± SE and the red dashed line ± 
SD.
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Association of FEV1 percent predicted and FEV1 / FVC % with total mucin. A) FEV1 % 
predicted is plotted against log total mucin(p=0.052). SS samples are represented by the 
solid circles and IS as open circles. Sample type was not significant in the model (p=0.333). 
B) FEV1 / FVC % is plotted against log total mucin (p=0.035). SS samples are represented 
by the solid circles and IS as open circles Sample type was not significant in the model 
(p=0.275). Significances for figures A and B are computed using mixed models.
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Table 1.
Screening demographics of patients with stable chronic bronchitis.
Age * 59.1 ± 10.6
Race Caucasian n (%) 59 (87%)
Sex Male n (%) 42 (61%)
Current Smoker n (%) 28 (41%)
Pack Years
+ 41.9 ± 25.4
FVC (percent predicted)
# 3.48 ± 0.96 (84.1%)
FEV1 (percent predicted)
# 2.01± 0.86 (63.4%)
FEV1/FVC
# 56.7 ± 15.5
GOLD Stage (no. in 0,1,2,3)
ǂ 15,3,28,22)
Reversibility
§ 11.8 ± 13.2
Inhaled Corticosteroid Use- Yes n
¶ 30 (44%) 69
*
Values are means ± SD
+
Pack Years = number of packs of cigarettes per day multiplied by the number of years smoked
#
Spirometry was measured post-bronchodilator, % predicted values utilized reference values from Hankinson
ǂ
GOLD Stage: GOLD 0= FEV1/FVC >0.7 and FEV1 % Predicted is >80%; GOLD 1= FEV1/FVC <0.7 and FEV1 % predicted >80%; Gold 2= 
FEV1/FVC <0.7 and FEV1 % predicted=50–79%; GOLD 3= FEV1/FVC <0.7 and FEV1 % predicted= 30–49%.
§
Reversibility calculated as ((post BD FEV1 - Pre BD FEV1)/Pre BD FEV1) x 100
¶
No duplicate subjects. Screening values for subjects participating in multiple aims were only utilized once.
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Table 2.
Nucleotide concentrations in SS and IS samples.




ADO 321.0 ± 408.4 (51) 276.0 ± 375.0 (76) 0.256 current Smoking p=0.002
AMP 2796.3 ± 4382.9 (54) 1745.2 ± 2762.3 (76) 0.091 ICS Use p=0.042
ADP 704.2 ± 682.4 (54) 602.6 ± 575.4 (76) 0.277 none
ATP 376.3 ± 499.1 (54) 280.3 ± 366.1 (76) 0.111 none
Total 3814.7 ± 3263.0 (51) 2904.3 ± 3050.6 (76) 0.085 none
*
Four subjects data was eliminated because of one or more nucleotide values >5 times the mean
ƚ
Significance determined in a mixed model
ǂ
Covariates included sample type, age, race, sex, current smoking, pack years,
FEV1 % Predicted, month of visit and ICS use
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Table 3.
Differential cell counts.
Cell SS n SS Mean ± SD IS n IS Mean ± SD p Value
Total cells/mg 45 4597 ± 7806 78 3583 ± 6685 0.486
% pmn 45 77 ± 17 78 77 ± 19 0.878
pmn cells/mg 45 4009 ± 7143 78 3132 ± 6341 0.511
% mac 45 18 ± 15 78 20 ± 19 0.468
mac cells/mg 45 465 ± 781 78 357 ± 468 0.460
% eos 45 2.8 ± 3.1 78 2.6 ± 4.2 0.145
eos cells/mg 45 98 ± 186 78 65 ± 122 0.219
% lym 45 0.5 ± 0.9 78 0.3 ± 0.4 0.087
lym cells/mg 45 12.2 ± 22.3 78 5.6 ± 19.4 0.087
% bec 45 1.4 ± 3.4 78 1.5 ± 3.3 0.960
bec cells/mg 45 11.7 ± 15.2 78 21.3 ± 36.9 0.092
% sec 45 16.4 ± 22.9 78 15.4 ± 18.8 0.665
pmn-polymorphonuclear leukocytes; mac-macrophages, eos-eosinophils;
lym-lymphocytes; bec-bronchial epithelial cells; sec-squamous epithelial cells
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Table 4.
Baseline means of inflammatory markers.
 SS Samples  IS Samples  
Cytokine N Mean SD  N Mean SD p Value
IL-1α 33 185.18 151.38 47 175.97 191.72 0.87
IL-1β 21 78.65 95.46 33 94.22 161.75 0.65
IL-2 12 61.96 145.07 19 43.48 89.80 0.95
IL-3 15 13991.37 53217.61 15 187.59 2109.28 0.28
IL-4 16 495.89 801.46 18 930.86 2302.60 0.53
IL-5 24 33.18 58.35 32 23.28 35.73 0.51
IL-6 29 1169.24 1482.07 44 934.57 1420.73 0.55
IL-7 20 729.69 1012.19 26 494.14 817.24 0.48
IL-8 34 16558.31 43031.87 51 12122.42 17692.20 0.50
IL-10 14 31.55 29.18 13 39.01 32.38 0.79
IL-12p40 10 366.75 269.48 15 631.29 2108.62 0.59
IL-12p70 24 69.29 212.25 34 38.83 51.59 0.41
IL-13 20 132.56 239.90 21 52.38 85.28 0.20
IL-15 26 53.64 61.05 39 34.07 9.87 0.10
GM-CSF 28 71.53 118.95 43 48.49 32.80 0.23
IFNɣ 24 116.04 233.31 35 94.92 117.62 0.66
TNFα 21 144.52 261.82 31 104.17 183.80 0.53
Eotaxin 20 14588.17 43634.48 20 5799.54 14784.55 0.45
MCP-1 36 4273.62 9140.79 52 3411.45 5689.27 0.42
RANTES 29 189.57 255.38 45 139.70 233.51 0.39
MIP-1α 23 1170.68 1277.62 34 613.74 765.54 0.05
IP-10 35 33769.88 51867.85 53 23021.31 38070.97 0.26
IL-17 10 331.30 310.02 16 579.92 482.21 0.95
MIP-1β 28 3588.90 10329.79 45 1340.06 1919.51 0.17
TNFR1 23 1098.62 1269.40 35 1322.13 1522.73 0.87
IFN-k 24 418.80 375.68 34 664.40 542.31 0.20
ENA-78 (CXCL5) 36 3701.29 5879.98 53 4913.47 7421.97 0.83
I-TAC (CXCL11) 22 894.43 988.85  36 759.04 1116.66 0.77
Only values that are within the limit of detection are reported
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